| Identification | Back Directory | [Name]
Dehydrocrenatidine | [CAS]
65236-62-6 | [Synonyms]
TOP3
TOP-3
TOP 3
Dehydrocrenatidine
O-Methylpicrasidine I
1-ethenyl-4,8-dimethoxy-9H-pyrido[3,4-b]indole
9H-Pyrido[3,4-b]indole, 1-ethenyl-4,8-dimethoxy- | [Molecular Formula]
C15H14N2O2 | [MDL Number]
MFCD17214777 | [MOL File]
65236-62-6.mol | [Molecular Weight]
254.28 |
| Hazard Information | Back Directory | [Uses]
Dehydrocrenatidine, a natural alkaloid, is a specific JAK inhibitor. Dehydrocrenatidine inhibits voltage-gated sodium channels and ameliorates mechanic allodia in a rat model of neuropathic pain[1][2]. | [in vivo]
Dehydrocrenatidine inhibits JAK-STAT3 dependent DU145 and MDA-MB-468 cell survival and induces cell apoptosis. Dehydrocrenatidine inhibits JAKs-JH1 domain over-expression induced STAT3 and STAT1 phosphorylations[1].
Dehydrocrenatidine diminishes IL-6, IFNα and IFNγ stimulated STAT3 phosphorylation as well as constitutive STAT3 phosphorylation[1].
DHCT suppresses both tetrodotoxin-resistant (TTX-R) and sensitive (TTX-S) voltage-gated sodium channel (VGSC) currents with IC50 values of 12.36 μM and 4.87 μM, respectively[2].
| [References]
[1] Jing Zhang, et al. Dehydrocrenatidine is a novel janus kinase inhibitor. Mol Pharmacol. 2015 Apr;87(4):572-81. DOI:10.1124/mol.114.095208
[2] Fang Zhao, et al. Dehydrocrenatidine Inhibits Voltage-Gated Sodium Channels and Ameliorates Mechanic Allodia in a Rat Model of Neuropathic Pain. Toxins (Basel). 2019 Apr 18;11(4):229. DOI:10.3390/toxins11040229 |
|
| Company Name: |
BioBioPha Co., Ltd.
|
| Tel: |
0871-65217109 13211707573; |
| Website: |
http://www.biobiopha.com |
|